Medical Council of Canada Updated MCCQE Exam Questions and Answers by mariam

Comprehensive and Detailed Explanation:

The most appropriate next step is to assess the patient’s capacity to consent to or refuse treatment. Patients with severe anorexia nervosa may lack decision-making capacity due todistorted thinking and perception, particularly if refusal of treatment is life-threatening. If she is found incapable, treatment can proceed in her best interests.

Toronto Notes 2023 – Psychiatry / Ethics:

“If a patient with anorexia nervosa refuses treatment but is medically unstable, assess capacity. If incapable, substitute decision-making may be initiated.”

MCCQE1 Objectives (ELOM > 90-4: Informed Consent and Capacity):

“Candidates must assess decision-making capacity when a patient refuses essential care, especially in life-threatening psychiatric or medical conditions.”

Psychiatric consult (B) may follow, but the immediate action is capacity assessment. D is premature without determining capacity. A and E are also premature or inappropriate.

—

Respecting patient autonomy requires understanding their perspective before offering persuasion or incentives. The best next step is to explore the reason for non-compliance. This builds rapport and informs a shared decision-making process.

Toronto Notes 2023 – ELOM, Patient-Centered Communication:

“When a patient refuses recommended treatment, explore the reason behind the refusal before proceeding. Shared decision-making is crucial.”

MCCQE1 Objectives – ELOM > Communication and Consent:

“Candidates must demonstrate an ability to explore reasons for treatment refusal before counseling or modifying management.”

Options B and C may follow later. Options D and E can undermine appropriate pharmacologic care or violate ethics if not consented.

====================================================

In discussions about end-of-life care, it is critical to shift the focus from the substitute decision-maker’s own feelings to what the patient would have wanted. This approach promotes ethically sound and patient-centered decisions. It is respectful, supportive, and maintains trust.

Toronto Notes 2023 – ELOM, “Advance Care Planning and End-of-Life Decisions”:

“When a patient cannot express wishes, decisions must be based on known prior wishes or substituted judgment—what the patient would have wanted.”

MCCQE1 Objectives (ELOM > 90-2: Capacity, Consent, and End-of-Life Care):

“Candidates must guide surrogate decision-makers toward reflecting on the patient’s values and previously expressed wishes.”

Options A and B are inappropriate—waiting without engagement or unilateral withdrawal is unethical. C does not address the wife’s emotional or ethical concerns. E is premature unless the wife is clearly unable or unfit to act as decision-maker.

====================================================

Spironolactone is a potassium-sparing diuretic that can cause hyperkalemia, especially in patients with impaired renal function. Hyperkalemia can lead to life-threatening arrhythmias, particularly wide complex tachycardia or ventricular fibrillation.

Toronto Notes 2023 – Cardiology and Nephrology, “Hyperkalemia” Section:

“Patients with CKD are at increased risk for hyperkalemia, particularly when taking potassium-sparing medications such as spironolactone. Severe hyperkalemia may cause bradycardia or wide-complex tachyarrhythmias.”

MCCQE1 Objectives (Internal Medicine > 76-2: Electrolyte Abnormalities):

“Candidates must recognize drug-induced hyperkalemia as a cause of cardiac arrhythmias, especially in patients with renal dysfunction.”

Hydrochlorothiazide (B) can cause hypokalemia. Metoprolol (C) and diltiazem (E) are rate-controlling agents but do not typically cause wide complex tachycardia. Clopidogrel (D) has no effect on cardiac conduction.

====================================================